DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone. Participants in the DOC1021 + pIFN + SOC arm will: * Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection * Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses * Receive subcutaneous pIFN injections weekly for a total of 6 doses in parallel with the DOC1021 injections Both arms of the trial will: \- Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive SOC treatment with surgery, temozolomide chemotherapy and radiation
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent musi wyrazić świadomą zgodę na udział w badaniu i przestrzegać jego zasad.
- •Pacjent musi mieć ukończone 18 lat.
- •Pacjent ma zdiagnozowanego glejaka mózgu (typ IDH-wt), który nadaje się do usunięcia operacyjnego.
- •Celem operacji jest całkowite lub prawie całkowite usunięcie guza.
- •Pacjent nie przyjmował wcześniej żadnego leczenia przeciwnowotworowego.
- •Pacjent musi być zdolny do przyjęcia leku filgrastim, przejścia zabiegu pobrania komórek krwi (leukaferezy) oraz otrzymać zastrzyki DOC1021 i pIFN.
- •Kobiety w wieku rozrodczym muszą mieć negatywny test ciążowy i stosować skuteczną antykoncepcję.
- •Pacjent musi mieć prawidłowe wyniki badań krwi (hemoglobina, liczba neutrofilów, płytki krwi) oraz odpowiednią funkcję nerek i wątroby.
✗ Disqualifies
- •Pacjenci, którzy otrzymali już jakiekolwiek leczenie przeciwnowotworowe z powodu glejaka mózgu, z wyjątkiem dodatkowej resekcji guza.
- •Pacjenci z niewydolnością nerek, wątroby lub szpiku kostnego.
- •Kobiety w ciąży lub karmiące piersią.
- •Pacjenci, którzy nie mogą przyjąć podanych leków lub przejść zaplanowanych procedur.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (18)
Banner MD Anderson Cancer Center
Gilbert, United States
City of Hope
Duarte, United States
HOAG
Newport Beach, United States
UCSF
San Francisco, United States
Baptist MD Anderson Cancer Center
Jacksonville, United States
Dana-Farber Cancer Institute
Boston, United States
Cooper University Health Care
Camden, United States
Rutgers Cancer Institute
New Brunswick, United States
Atlantic Health
Summit, United States
Lenox Hill Hospital
New York, United States
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, United States
Wake Forest University Health Sciences
Winston-Salem, United States
The Ohio State University Comprehensive Cancer Center
Columbus, United States
UPMC Presbyterian Hospital
Pittsburgh, United States
Vanderbilt-Ingram Cancer Center
Nashville, United States
UTHealth Houston
Houston, United States
Baylor College of Medicine
Houston, United States
The University of Texas Health Science Center at San Antonio
San Antonio, United States
Trial contact
Zorica Simic
Jana Portnow, MD
PRINCIPAL_INVESTIGATOR
Julie Nguyen
Simon Khagi, MD
PRINCIPAL_INVESTIGATOR
Stephanie Lewis
Thomas Nelson, MD
PRINCIPAL_INVESTIGATOR
Andres Alvarez, MD
Robert Cavaliere, MD
PRINCIPAL_INVESTIGATOR
Indira Balmasheva
Sean Behnke
Alan Turtz, MD
PRINCIPAL_INVESTIGATOR
Xiaoru Chen
Morana Vojnic, MD
PRINCIPAL_INVESTIGATOR
Morgan Finlay
Robert Aiken, MD
PRINCIPAL_INVESTIGATOR
Sara Massimo
John Boockvar, MD
Claire Kowalczyk
Dominique Higgins, MD
PRINCIPAL_INVESTIGATOR
Roy E Strowd III, MD
PRINCIPAL_INVESTIGATOR
Clinical Research Coordinator
J. Bradley Elder, MD
PRINCIPAL_INVESTIGATOR
Theodore Estep
Costas Hadjipanayis, MS, MD, PhD
PRINCIPAL_INVESTIGATOR
VICC CTIP (Clinical Trials Info Program)
Ryan Merrell, MD
PRINCIPAL_INVESTIGATOR
Austin Lu
Nitin Tandon, MD
PRINCIPAL_INVESTIGATOR
Glenn Wilson
Jacob Mandel, MD
PRINCIPAL_INVESTIGATOR
Leti Velten, RN
Andrew Brenner, MD, PhD
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.